Cannabinoids and the skeleton: From marijuana to reversal of bone loss

Annals of Medicine

Volumn 41, Issue 8, 2009, Pages 560-567

  Bab, Itai ^a   Zimmer, Andreas ^b   Melamed, Eitan ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

Bone; Cannabinoid; Endocannabinoid; Marijuana; Osteoporosis

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 4 [4 (1,1 DIMETHYLHEPTYL) 2,6 DIMETHOXYPHENYL] 6,6 DIMETHYLBICYCLO[3.1.1]HEPT 2 EN 2 YLMETHANOL; AM 360; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID DERIVATIVE; CANNABINOID RECEPTOR AGONIST; CANNABIS; DRONABINOL; ENDOCANNABINOID; LIGAND; UNCLASSIFIED DRUG;

ADRENERGIC ACTIVITY; BONE; BONE CELL; BONE MASS; BONE REMODELING; BRAIN LEVEL; CELL ACTIVITY; CELL DIFFERENTIATION; CNR2 GENE; DISEASE PREDISPOSITION; GENE; GENETIC POLYMORPHISM; HUMAN; NERVE ENDING; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; OVARIECTOMY; PHENOTYPE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK ASSESSMENT; SKELETON; SYMPATHETIC NERVE; TISSUE;

ANIMALS; BONE AND BONES; CANNABINOIDS; CANNABIS; DRUG DELIVERY SYSTEMS; ENDOCANNABINOIDS; HUMANS; MICE; OSTEOPOROSIS; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; TETRAHYDROCANNABINOL;

EID: 72949117074     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.1080/07853890903121025     Document Type: Review

References (86)

1. Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci. 2003;4:873-884
2. Lambert DM, Fowler CJ. The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications. J Med Chem. 2005;48:5059-5087
3. Hohmann AG, Suplita RL 2nd. Endocannabinoid mechanisms of pain modulation. AAPS J. 2006;8:E693-708.
4. Pertwee RG. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol. 2006;147(Suppl 1):S163-71.
5. Kogan NM, Mechoulam R. Cannabinoids in health and disease. Dialogues Clin Neurosci. 2007;9:413-430
6. Marx J. Drug development. Drugs inspired by a drug. Science. 2006;311:322-325
7. Yazulla S. Endocannabinoids in the retina: From marijuana to neuroprotection. Prog Retin Eye Res. 2008;27:501-526
8. Iversen L. The science of marijuana. New York: Oxford University Press, 2000.
9. Mechoulam R. Discovery of endocannabinoids and some random thoughts on their possible roles in neuroprotection and aggression. Prostaglandins Leukot Essent Fatty Acids. 2002;66:93-99
10. Iversen L. Cannabis and the brain. Brain. 2003;126: 1252-1270
11. Akbas F, Gasteyger C, Sjodin A, Astrup A, Larsen TM. A critical review of the cannabinoid receptor as a drug target for obesity management. Obes Rev. 2009;10:58-67.
12. Bab I. The skeleton: stone bones and stoned heads? In: Mechoulam R, editor. Cannabinoids as therapeutics. Milestones in drug therapy series. Basel: Birkhauser Verlag, 2005. p. 201-206
13. Idris AI, van 't Hof RJ, Greig IR, Ridge SA, Baker D, Ross RA, et al. Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nat Med. 2005;11:774-779
14. Bab I, Hajbi-Yonissi C, Gabet Y, Muller R. Micro-tomographic atlas of the mouse skeleton. New York: Springer, 2007. p. 195-199
15. Parfitt AM. The coupling of bone formation to bone resorption: a critical analysis of the concept and of its relevance to the pathogenesis of osteoporosis. Metab Bone Dis Relat Res. 1982;4:1-6.
16. Roodman GD. Cell biology of the osteoclast. Exp Hematol. 1999;27:1229-1241
17. Bab I, Ashton BA, Gazit D, Marx G, Williamson MC, Owen ME. Kinetics and differentiation of marrow stromal cells in diffusion chambers in vivo. J Cell Sci. 1986;84:139-151
18. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev. 2000;21:115-137
19. Poli V, Balena R, Fattori E, Markatos A, Yamamoto M, Tanaka H, et al. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J. 1994;13:1189-1196
20. Suda T, Kobayashi K, Jimi E, Udagawa N, Takahashi N. The molecular basis of osteoclast differentiation and activation. Novartis Found Symp. 2001;232:235-237
21. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89: 309-319
22. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93:165-176
23. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, et al. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998;12:1260-1268
24. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999;397:315-323
25. Yoshida Y, Tanaka S, Umemori H, Minowa O, Usui M, Ikematsu N, et al. Negative regulation of BMP/Smad signaling by Tob in osteoblasts. Cell. 2000;103:1085-1097
26. Bodine PV, Komm BS. Wnt signaling and osteoblastogenesis. Rev Endocr Metab Disord. 2006;7:33-39
27. Most W, van der Wee-Pals L, Ederveen A, Papapoulos S, Lowik C. Ovariectomy and orchidectomy induce a transient increase in the osteoclastogenic potential of bone marrow cells in the mouse. Bone. 1997;20:27-30.
28. Gabet Y, Kohavi D, Muller R, Chorev M, Bab I. Intermittently administered parathyroid hormone 1-34 reverses bone loss and structural impairment in orchiectomized adult rats. Osteoporos Int. 2005;16:1436-1443
29. Alexander JM, Bab I, Fish S, Muller R, Uchiyama T, Gronowicz G, et al. Human parathyroid hormone 1-34 reverses bone loss in ovariectomized mice. J Bone Miner Res. 2001;16:1665-1673
30. Potts JT, Juppner H. Parathyroid hormone and parathyroid hormone-related peptide in calcium homeostasis, bone metabolism, and bone development: the proteins, their genes, and receptors. San Diego: Academic Press, 1998.
31. Gunther T, Chen ZF, Kim J, Priemel M, Rueger JM, Amling M, et al. Genetic ablation of parathyroid glands reveals another source of parathyroid hormone. Nature. 2000;406: 199-203.
32. Nicholson GC, Moseley JM, Sexton PM, Mendelsohn FA, Martin TJ. Abundant calcitonin receptors in isolated rat osteoclasts. Biochemical and autoradiographic characterization. J Clin Invest. 1986;78:355-360
33. Yakar S, Rosen CJ, Beamer WG, Ackert-Bicknell CL, Wu Y, Liu JL, et al. Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest. 2002;110:771-781
34. Bab I, Chorev M. Osteogenic growth peptide: from concept to drug design. Biopolymers. 2002;66:33-38
35. Yadav VK, Ryu JH, Suda N, Tanaka KF, Gingrich JA, Schütz G, et al. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell. 2008;135:825-837
36. Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell. 2000;100: 197-207.
37. Baldock PA, Sainsbury A, Couzens M, Enriquez RF, Thomas GP, Gardiner EM, et al. Hypothalamic Y2 receptors regulate bone formation. J Clin Invest. 2002;109:915-921
38. Takeda S, Elefteriou F, Levasseur R, Liu X, Zhao L, Parker KL, et al. Leptin regulates bone formation via the sympathetic nervous system. Cell. 2002;111:305-317
39. Abe E, Marians RC, Yu W, Wu XB, Ando T, Li Y, et al. TSH is a negative regulator of skeletal remodeling. Cell. 2003;115: 151-162
40. Sun L, Peng Y, Sharrow AC, Iqbal J, Zhang Z, Papachristou DJ, et al. FSH directly regulates bone mass. Cell. 2006;125: 247-260
41. Howlett AC. The cannabinoid receptors. Prostaglandins Other Lipid Mediat. 2002;68-69:619-631
42. Julien B, Grenard P, Teixeira-Clerc F, Van Nhieu JT, Li L, Karsak M, et al. Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology. 2005;128: 742-755
43. Steffens S, Veillard NR, Arnaud C, Pelli G, Burger F, Staub C, et al. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature. 2005;434: 782-786
44. Shire D, Calandra B, Bouaboula M, Barth F, Rinaldi-Carmona M, Casellas P, et al. Cannabinoid receptor interactions with the antagonists SR 141716A and SR 144528. Life Sci. 1999;65:627-635
45. Hanus L, Breuer A, Tchilibon S, Shiloah S, Goldenberg D, Horowitz M, et al. HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc Natl Acad Sci USA. 1999;96:14228-14233
46. Howlett AC. Cannabinoid receptor signaling. Handb Exp Pharmacol. 2005:53-79.
47. Lauckner JE, Jensen JB, Chen HY, Lu HC, Hille B, Mackie K. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci U S A. 2008;105:2699-2704
48. Pertwee RG. GPR55: a new member of the cannabinoid receptor clan? Br J Pharmacol. 2007;152:984-986
49. De Petrocellis L, Bisogno T, Maccarrone M, Davis JB, Finazzi-Agro A, Di Marzo V. The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism. J Biol Chem. 2001;276:12856-12863
50. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258: 1946-1949
51. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol. 1995;50:83-90.
52. Hansen HS, Moesgaard B, Hansen HH, Petersen G. N-Acylethanolamines and precursor phospholipids*relation to cell injury. Chem Phys Lipids. 2000;108:135-150
53. Willoughby KA, Moore SF, Martin BR, Ellis EF The biodisposition and metabolism of anandamide in mice. J Pharmacol Exp Ther. 1997;282:243-247
54. Simon GM, Cravatt BF. Endocannabinoid biosynthesis proceeding through glycerophospho-N-acyl ethanolamine and a role for alpha/beta-hydrolase 4 in this pathway. J Biol Chem. 2006;281:26465-26472
55. Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR, et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA. 2001;98:9371-9376
56. Varga K, Wagner JA, Bridgen DT, Kunos G. Platelet-and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J. 1998;12: 1035-1044
57. Di Marzo V, Bisogno T, De Petrocellis L, Melck D, Orlando P, Wagner JA, et al. Biosynthesis and inactivation of the endocannabinoid 2- arachidonoylglycerol in circulating and tumoral macrophages. Eur J Biochem. 1999;264:258-267
58. Stella N, Schweitzer P, Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature. 1997;388:773-778
59. Bisogno T, Howell F, Williams G, Minassi A, Cascio MG, Ligresti A, et al. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J Cell Biol. 2003;163:463-468
60. Konrad RJ, Major CD, Wolf BA. Diacylglycerol hydrolysis to arachidonic acid is necessary for insulin secretion from isolated pancreatic islets: sequential actions of diacylglycerol and monoacylglycerol lipases. Biochemistry. 1994;33: 13284-13294
61. Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature. 2001;410:822-825
62. Orzel JA, Rudd TG. Heterotopic bone formation: clinical, laboratory, and imaging correlation. J Nucl Med. 1985;26: 125-132
63. Wildburger R, Zarkovic N, Tonkovic G, Skoric T, Frech S, Hartleb M, et al. Post-traumatic hormonal disturbances: prolactin as a link between head injury and enhanced osteogenesis. J Endocrinol Invest. 1998;21:78-86.
64. Panikashvili D, Simeonidou C, Ben-Shabat S, Hanus L, Breuer A, Mechoulam R, et al. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature. 2001;413:527-531
65. Bab I, Ofek O, Tam J, Rehnelt J, Zimmer A. Endocannabi-noids and the regulation of bone metabolism. J Neuroendo-crinol. 2008;20(Suppl 1):69-74.
66. Tam J, Trembovler V, Di Marzo V, Petrosino S, Leo G, Alexandrovich A, et al. The cannabinoid CB1 receptor regulates bone formation by modulating adrenergic signaling. FASEB J. 2008;22:285-294
67. Rossi F, Siniscalco D, Luongo L, De Petrocellis L, Bellini G, Petrosino S, et al. The endovanilloid/endocannabinoid system in human osteoclasts: possible involvement in bone formation and resorption. Bone. 2009;44:476-484
68. Bab I, Zimmer A. Cannabinoid receptors and the regulation of bone mass. Br J Pharmacol. 2008;153:182-188
69. Hanus L, Abu-Lafi S, Fride E, Breuer A, Vogel Z, Shalev DE, et al. 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci USA. 2001;98:3662-3665
70. Ofek O, Karsak M, Leclerc N, Fogel M, Frenkel B, Wright K, et al. Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci USA. 2006;103:696-701.
71. Scutt A, Williamson EM. Cannabinoids stimulate fibroblastic colony formation by bone marrow cells indirectly via CB2 receptors. Calcif Tissue Int. 2007;80:50-59
72. George KL, Saltman LH, Stein GS, Lian JB, Zurier RB. Ajulemic acid, a nonpsychoactive cannabinoid acid, suppresses osteoclastogenesis in mononuclear precursor cells and induces apoptosis in mature osteoclast-like cells. J Cell Physiol. 2008;214:714-720
73. Idris AI, Sophocleous A, Landao-Bassonga E, van 't Hof RJ, Ralston SH. Regulation of bone mass, osteoclast function, and ovariectomy-induced bone loss by the type 2 cannabinoid receptor. Endocrinology. 2008;149:5619-5626
74. Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, et al. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science. 1999;283:401-.
75. Tam J, Ofek O, Fride E, Ledent C, Gabet Y, Müller R, et al. Involvement of neuronal cannabinoid receptor CB1 in regulation of bone mass and bone remodeling. Mol Pharmacol. 2006;70:786-792
76. Amor S, Smith PA, Hart B, Baker D. Biozzi mice: of mice and human neurological diseases. J Neuroimmunol. 2005; 165:1-10.
77. Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI. Increased mortality, hypoactivity, and hypoalge-sia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci USA. 1999;96:5780-5785 (Pubitemid 29234695)
78. Brown JP, Delmas PD, Malaval L, Edouard C, Chapuy MC, Meunier PJ. Serum bone Gla-protein: a specific marker for bone formation in postmenopausal osteoporosis. Lancet. 1984;1:1091-1093
79. Nogueira-Filho Gda R, Cadide T, Rosa BT, Neiva TG, Tunes R, Peruzzo D, et al. Cannabis sativa smoke inhalation decreases bone filling around titanium implants: a histomor-phometric study in rats. Implant Dent. 2008;17:461-470
80. McCaw E, Hu H, Gomez GT, Hebb AL, Kelly ME, Denovan-Wright EM. Structure, expression and regulation of the cannabinoid receptor gene (CB1) in Huntington's disease transgenic mice. Eur J Biochem. 2004;271:4909-4920
81. Zhang P, Ishiguro H, Ohtsuki T, Hess J, Carillo F, Walther D, et al. Human cannabinoid receptor 1: 5? exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse. Mol Psychiatry. 2004;9: 916-931
82. Devoto M, Shimoya K, Caminis J, Ott J, Tenenhouse A, Whyt MP, et al. First-stage autosomal genome screen in extended pedigrees suggests genes predisposing to low bone mineral density on chromosomes 1p, 2p and 4q. Eur J Hum Genet. 1998;6:151-157
83. Devoto M, Specchia C, Li HH, Caminis J, Tenenhouse A, Rodriguez H, et al. Variance component linkage analysis indicates a QTL for femoral neck bone mineral density on chromosome 1p36. Hum Mol Genet. 2001;10:2447-2452
84. Devoto M, Spotila LD, Stabley DL, Wharton GN, Rydbeck H, Korkko J, et al. Univariate and bivariate variance component linkage analysis of a whole-genome scan for loci contributing to bone mineral density. Eur J Hum Genet. 2005;13:781-788
85. Karsak M, Cohen-Solal M, Freudenberg J, Ostertag A, Morieux C, Kornak U, et al. Cannabinoid receptor type 2 gene is associated with human osteoporosis. Hum Mol Genet. 2005;14:3389-3396
86. Yamada Y, Ando F, Shimokata H. Association of candidate gene polymorphisms with bone mineral density in community-dwelling Japanese women and men. Int J Mol Med. 2007;19:791-801.